Bank of Montreal Can Purchases New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of Montreal Can acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,597,002 shares of the biotechnology company’s stock, valued at approximately $17,886,000. Bank of Montreal Can owned 0.69% of ADMA Biologics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Viewpoint Capital Management LLC increased its position in ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 2,416 shares during the last quarter. Quest Partners LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $29,000. Arizona State Retirement System increased its holdings in ADMA Biologics by 4.5% in the second quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,645 shares during the last quarter. Eagle Asset Management Inc. raised its position in ADMA Biologics by 20.2% during the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 4,367 shares in the last quarter. Finally, CWM LLC lifted its stake in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $19.39 on Friday. The firm has a market capitalization of $4.49 billion, a PE ratio of -969.25 and a beta of 0.61. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $20.16. The firm’s fifty day simple moving average is $16.39 and its 200 day simple moving average is $11.39.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period in the previous year, the company posted ($0.02) earnings per share. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. On average, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Transactions at ADMA Biologics

In other news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the sale, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 over the last three months. 3.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ADMA has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Mizuho raised their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright upped their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.